Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1984086 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $33.61Day −1.06%Mkt cap $1.5B1Y +163.6%Off 52W high −11.6%Vol (1Y) 65.1%
Daily closing price, split-adjusted to the current basis; 1.7y shown of 436 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest7.4% of sh out |
| Days to cover5.7d |
| 13F net flow (QoQ)+0.31% |
| Top-10 13F concentration74.9% |
| Next report (est.)2026-08-08 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$72.3M |
| Earnings (TTM)-$36.0M |
| ROE−12.2% |
| Net margin−106.4% |
| ROIC−24.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+20.6% |
| 1Y+163.6% |
| Since incept. (ann.)+29.3% |
Total return through 2026-07-29 · series begins 2024-10-25. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)65.1% |
| Ann. volatility (3Y)92.1% |
| Sharpe (1Y)1.70 |
| Sharpe (3Y)0.76 |
| Max drawdown (1Y)−25.2% |
| Max drawdown (3Y)−81.5% |
| Beta (3Y vs SPY)2.20 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 7.0M | $168M | 15.52% | +0.0% |
| TRV GP V, LLC | 6.2M | $149M | 13.79% | +0.0% |
| Driehaus Capital Management LLC | 4.4M | $106M | 9.75% | −8.6% |
| TRV GP VI, LLC | 4.2M | $101M | 9.34% | +0.0% |
| SAMSARA BIOCAPITAL, LLC | 3.1M | $76M | 6.99% | +0.0% |
| GOLDMAN SACHS GROUP INC | 2.9M | $70M | 6.45% | +7.0% |
| Siren, L.L.C. | 2.0M | $48M | 4.44% | +0.0% |
| BlackRock, Inc. | 1.8M | $44M | 4.04% | +1.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 101.9% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 2,067,671 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-11 | −$0.19 | — | $26.5M | +12011.0% |
| 2025-12-31 | 2026-03-09 | — | — | $24.1M | +11276.4% |
| 2025-09-30 | 2025-11-10 | $0.18 | — | $21.5M | +12113.1% |
| 2025-06-30 | 2025-08-11 | −$0.56 | — | $119,000 | −67.8% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-08 is ESTIMATED from filing cadence (median gap 89d) — not company-confirmed.
